ACHC
Acadia Healthcare Company, Inc.
ACHC lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
ACHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Weak |
ACHC's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
ACHC PE Valuation
ACHC has no meaningful PE right now: it lost money over the past year.
ACHC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for ACHC, with profitability improving. However, they disagree widely on these estimates.
ACHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | — |
| Q3 2026 | -$12.43 | -1153% |
| Q2 2026 | -$12.41 | -916% |
| Q1 2026 | -$12.20 | -698% |
| Q4 2025 | -$12.16 | -537% |
| Q3 2025 | $1.18 | -61% |
| Q2 2025 | $1.52 | +$1.59 |
| Q1 2025 | $2.04 | +$2.17 |
| Q4 2024 | $2.78 | +$3.02 |
ACHC has swung to a loss: it lost $12.43 per share over the past year, after a profit the year before.
ACHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $895.3M | +5.1% |
| Q2 2026 | $865.8M | -0.4% |
| Q1 2026 | $828.8M | +7.6% |
| Q4 2025 | $821.5M | +6.1% |
| Q3 2025 | $851.6M | +4.4% |
| Q2 2025 | $869.2M | +9.2% |
| Q1 2025 | $770.5M | +0.3% |
| Q4 2024 | $774.2M | +4.2% |
ACHC's revenue is growing: $895M last quarter, up 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.3% | +1.6 points |
| Q2 2026 | 2.5% | -3.2 points |
| Q1 2026 | 1.3% | -0.4 points |
| Q4 2025 | -142% | -147 points |
| Q3 2025 | 4.7% | -7.4 points |
| Q2 2025 | 5.8% | -7.6 points |
| Q1 2025 | 1.8% | -11 points |
| Q4 2024 | 4.9% | -5.9 points |
ACHC's operating margin was 6.3% last quarter, up 1.6 points from the same quarter a year ago.
ACHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.1M | +$110.2M |
| Q2 2026 | $123.5M | +$157.8M |
| Q1 2026 | -$15M | +$148.1M |
| Q4 2025 | -$179.5M | -$92.7M |
| Q3 2025 | -$63M | -$35.9M |
| Q2 2025 | -$34.2M | -303% |
| Q1 2025 | -$163.2M | +$300.5M |
| Q4 2024 | -$86.8M | -$64.4M |
ACHC has burned cash in six of the last eight quarters: −$24M over the past year, against −$347M the year before.
ACHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 6.8x | High |
| Q2 2025 | 5.7x | High |
| Q1 2025 | 5.1x | High |
| Q4 2024 | 3.8x | Elevated |
| Q3 2024 | 3.4x | Elevated |
| Q2 2024 | 12.7x | High |
| Q1 2024 | 14.2x | High |
| Q4 2023 | 11.9x | High |
ACHC's net debt is about 6.8 years of its operating earnings (EBITDA), up from 3.4 years a year ago.
ACHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.3 | Overbought |
| Stochastic | 70.2 | Neutral |
ACHC's weekly RSI is 70 (overbought) and its Stochastic is 70 (neutral).
ACHC PE vs Healthcare Sector
| Metric | ACHC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACHC has no meaningful PE right now: it lost money over the past year.
ACHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.5 | 20% above |
| 20 week MA | $30.9 | 23% above |
| 50 week MA | $24.8 | 52% above |
| 100 week MA | $25.9 | 46% above |
| 200 week MA | $48.6 | 22% below |
ACHC has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 22% below its 200-week average.
ACHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.0 | $49.3 | +49% |
| 2021 | $49.3 | $59.1 | +20% |
| 2022 | $59.1 | $83.0 | +40% |
| 2023 | $83.0 | $77.8 | -6.3% |
| 2024 | $77.8 | $38.0 | -51% |
| 2025 | $38.0 | $14.7 | -61% |
| 2026 YTD | $14.7 | $37.8 | +157% |
ACHC has finished three years in a row lower, and it's up 157% so far in 2026.